Skip to main content
SpringerLink
Log in

Phaeochromocytoma and Paraganglioma

  • Chapter
Hypertension: from basic research to clinical practice

Part of the book series: Advances in Experimental Medicine and Biology ((AIM,volume 956))

Abstract

Phaeochromocytomas and paragangliomas are relatively uncommon tumours which may be manifest in many ways, specifically as sustained or paroxysmal hypertension, episodes of palpitations, sweating, headache and anxiety, or increasingly as an incidental finding. Recent studies have shown that an increasing number are due to germline mutations. This review concentrates on the diagnosis, biochemistry and treatment of these fascinating tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Amar L, Servais A, Gimeniz-Roqueplo AP et al (2005) Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 90:2110–2116

    Article  CAS  PubMed  Google Scholar 

  • Andersen KF, Altaf R, Krarup-Hansen A et al (2011) Malignant pheochromocytomas and paragangliomas—the importance of a multidisciplinary approach. Cancer Treat Rev 37(2):111–119

    Article  PubMed  Google Scholar 

  • Assalia A, Gagner M (2004) Laparoscopic adrenalectomy. Br J Surg 91:1259–1274

    Article  CAS  PubMed  Google Scholar 

  • Baguet JP, Hammer L, Mazzuco TL et al (2004) Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol 150:681

    Article  CAS  PubMed  Google Scholar 

  • Baid SK, Lai EW, Wesley RA, Ling A, Timmers HJ, Adams KT, Kozupa A, Pacak K (2009) Brief communication: radiographic contrast infusion and catecholamine release in patients with pheochromocytoma. Ann Intern Med 150(1):27–32. Erratum in: Ann Intern Med. 2009 Feb 17;150(4):292

    Article  PubMed  PubMed Central  Google Scholar 

  • Barnes L, Taylor SR (1990) Carotid body paragangliomas. A clinicopathologic and DNA analysis of 13 tumors. Arch Otolaryngol Head Neck Surg 116

    Google Scholar 

  • Beard CM, Sheps SG, Kurland LT et al (1983) Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 58:802

    CAS  PubMed  Google Scholar 

  • Bergland BE (1989) Pheochromocytoma presenting as shock. Am J Emerg Med 7:44–48

    Article  CAS  PubMed  Google Scholar 

  • Berglund AS, Hulthén UL, Manhem P, Thorsson O, Wollmer P, Törnquist C (2001) Metaiodobenzylguanidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of phaeochromocytomas. J Intern Med 249:247–251

    Article  CAS  PubMed  Google Scholar 

  • Bhatia KS, Ismail MM, Sahdev A et al (2008) 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) 69:181–188

    Article  Google Scholar 

  • Blake MA et al (2004) Pheochromocytoma. An Imaging Chameleon. Radiographics 24:87–99

    Article  Google Scholar 

  • Bravo EL (1991) Pheochromocytoma: new concepts and future trends. Kidney Int 40:544

    Article  CAS  PubMed  Google Scholar 

  • Brito JP, Asi N, Bancos I, Gionfriddo MR, Zeballos-Palacios CL, Leppin AL, Undavalli C, Wang Z, Domecq JP, Prustsky G, Elraiyah TA, Prokop LJ, Montori VM, Murad MH (2015) Testing for germline mutations in sporadic pheochromocytoma/paraganglioma: a systematic review. Clin Endocrinol (Oxf) 82(3):338–345. doi:10.1111/cen.12530, Epub 2014 Jul 7

    Article  CAS  Google Scholar 

  • Brunaud L, Ayav A, Zarnegar R et al (2008) Prospective evaluation of 100 robotic-assisted unilateral adrenalectomies. Surgery 144:995–1001

    Article  PubMed  Google Scholar 

  • Buchmann I, Henze M, Engelbrecht S et al (2007) Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34(10):1617–1626

    Article  CAS  PubMed  Google Scholar 

  • Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F et al (2011) Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 43:663–777

    Article  CAS  PubMed  Google Scholar 

  • Därr R, Pamporaki C, Peitzsch M, Miehle K, Prejbisz A et al (2014) Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin Endocrinol (Oxf) 80(4):478–486. doi:10.1111/cen.12327

    Article  Google Scholar 

  • Dénes J, Swords F, Rattenberry E, Stals K, Owens M, Cranston T, Xekouki P, Moran L, Kumar A, Wassif C, Fersht N, Baldeweg SE, Morris D, Lightman S, Agha A, Rees A, Grieve J, Powell M, Boguszewski CL, Dutta P, Thakker RV, Srirangalingam U, Thompson CJ, Druce M, Higham C, Davis J, Eeles R, Stevenson M, O’Sullivan B, Taniere P, Skordilis K, Gabrovska P, Barlier A, Webb SM, Aulinas A, Drake WM, Bevan JS, Preda C, Dalantaeva N, Ribeiro-Oliveira A Jr, Garcia IT, Yordanova G, Iotova V, Evanson J, Grossman AB, Trouillas J, Ellard S, Stratakis CA, Maher ER, Roncaroli F, Korbonits M (2015) Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metab 100(3):E531–E541. doi:10.1210/jc.2014-3399, Epub 2014 Dec 12

    Article  PubMed  Google Scholar 

  • Dluhy RG (2002) Pheochromocytoma-death of an axiom. N Engl J Med 346:1486

    Article  PubMed  Google Scholar 

  • Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB (2009) Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res 41(9):697–702. doi:10.1055/s-0029-1220687, Epub 2009 May 7

    Article  CAS  PubMed  Google Scholar 

  • Eisenhofer G (2012) Screening for pheochromocytomas and paragangliomas. Curr Hypertens Rep 14:130–137. doi:10.1007/s11906-012-0246-y

    Article  CAS  PubMed  Google Scholar 

  • Eisenhofer G, Walther MM, Huynh TT et al (2001) Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 86:1999

    Article  CAS  PubMed  Google Scholar 

  • Eisenhofer G, Kopin IJ, Goldstein DS (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56:331–349

    Article  CAS  PubMed  Google Scholar 

  • Eisenhofer G et al (2012) Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 48(11):1739–1749

    Article  CAS  PubMed  Google Scholar 

  • Ferreira VM, Marcelino M, Piechnik SK, Marini C, Karamitsos TD, Ntusi NAB, Francis JM, Robson MD, Arnold JR, Mihai R, Thomas JD, Herincs M, Hassan-Smith Z, Karavitaki N, Greiser A, Arlt W, Korbonits M, Grossman A, Wass J, Neubauer S (2016) Pheochromocytoma is characterized by catecholamine myocarditis, focal and diffuse fibrosis, and persistent subclinical systolic and diastolic dysfunction. J Am Coll Cardiol, in press

    Google Scholar 

  • Forrer F, Riedweg I, Maecke HR, Mueller-Brand J (2008) Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 52(4):334–340

    CAS  PubMed  Google Scholar 

  • Galan SR, Kann PH (2013) Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma. Clin Endocrinol (Oxf) 78(2):165–175

    Article  CAS  Google Scholar 

  • Grosse H, Schröder D, Schober O, Hausen B, Dralle H (1990) The importance of high-dose alpha-receptor blockade for blood volume and hemodynamics in pheochromocytoma [in German]. Anaesthesist 39:313–318

    CAS  PubMed  Google Scholar 

  • Grossman A, Pacak K, Sawka A et al (2006) Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? Ann N Y Acad Sci 1073:332–347

    Article  CAS  PubMed  Google Scholar 

  • Guerrero MA, Schreinemakers JM, Vriens MR et al (2009) Clinical spectrum of pheochromocytoma. J Am Coll Surg 209:727

    Article  PubMed  Google Scholar 

  • Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A et al (2014) SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 135(11):2711–2720. doi:10.1002/ijc.28913

    Article  CAS  PubMed  Google Scholar 

  • Hofmann M, Maecke H, Bo ̈rner AR et al (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 28(12):1751–1757

    Article  CAS  PubMed  Google Scholar 

  • Ilias I, Yu J, Carrasquillo JA et al (2003) Superiority of 6- [18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 88(9):4083–4087

    Article  CAS  PubMed  Google Scholar 

  • Jacobson AF, Deng H, Lombard J, Lessig HJ, Black RR (2010) 123I -meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab 95:2596–2606

    Article  CAS  PubMed  Google Scholar 

  • Jalil ND, Pattou FN, Combemale F et al (1998) Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas: a review of 282 cases. French Association of Surgery (AFC), and The French Association of Endocrine Surgeons (AFCE). Eur J Surg 164:23–28

    Article  CAS  PubMed  Google Scholar 

  • Janssen I, Blanchet EM, Adams K et al (2015) Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res 21(17):3888–3895. doi:10.1158/1078-0432.CCR-14-2751

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kantorovich V, King KS, Pacak K (2010) SDH-related pheochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab 24(3):415–424. doi:10.1016/j.beem.2010.04.001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y (2005) Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16(1):23–32

    Article  PubMed  Google Scholar 

  • Kliewer KE, Cochran AJ (1989) A review of the histology, ultrastructure, immunohistology, and molecular biology of extra-adrenal paragangliomas. Arch Pathol Lab Med 113:1209

    CAS  PubMed  Google Scholar 

  • Kliewer KE, Wen DR, Cancilla PA, Cochran AJ (1989) Paragangliomas: assessment of prognosis by histologic, immunohistochemical, and ultrastructural techniques. Hum Pathol 20:29

    Article  CAS  PubMed  Google Scholar 

  • Kocak S, Aydintug S, Canakci N (2002) Alpha blockade in preoperative preparation of patients with pheochromocytomas. Int Surg 87:191–194

    PubMed  Google Scholar 

  • Korevaar TI, Grossman AB (2011) Pheochromocytomas and paragangliomas: assessment of malignant potential. Endocrine 40(3):354–365. doi:10.1007/s12020-011-9545-3, Epub 2011 Oct 25

    Article  CAS  PubMed  Google Scholar 

  • Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW et al (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401–406

    Article  CAS  PubMed  Google Scholar 

  • Kwekkeboom DJ, De Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177Lu- DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26(13):2124–2130

    Article  CAS  PubMed  Google Scholar 

  • Lenders JW, Eisenhofer G, Mannelli M, Pacak K (2005) Phaeochromocytoma. Lancet 366:665–675

    Article  PubMed  Google Scholar 

  • Lenders JWM, Duh QY et al (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(6):1915–1942

    Article  CAS  PubMed  Google Scholar 

  • Liao WB, Liu CF, Chiang CW et al (2000) Cardiovascular manifestations of pheochromocytoma. Am J Emerg Med 18:622–625

    Article  CAS  PubMed  Google Scholar 

  • Linnoila RI, Keiser HR, Steinberg SM, Lack EE (1990) Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21(11):1168–1180

    Article  CAS  PubMed  Google Scholar 

  • Liu TH, Chen YJ, Wu SF et al (2004) Distinction between benign and malignant pheochromocytomas. Zhonghua Bing Li Xue Za Zhi 33(3):198–202

    PubMed  Google Scholar 

  • Loh KC, Fitzgerald PA, Matthay KK, Yeo PPB, Price DC (1997) The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Investig 20(11):648–658

    Article  CAS  Google Scholar 

  • Maithel SK, Fong Y (2009) Hepatic ablation for neuroendocrine tumor metastases. J Surg Oncol 100(8):635–638

    Article  PubMed  Google Scholar 

  • Malchoff CD, MacGillivray D, Shichman S (2004) Pheochromocytoma treatment. In: Mansoor GA (ed) Secondary hypertension. Humana Press, Totowa, pp 235–249

    Chapter  Google Scholar 

  • Mamede M et al (2006) Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun 27(1):31–36

    Article  PubMed  Google Scholar 

  • Mantero F, Terzolo M, Arnaldi G et al (2000) A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85:637–644

    CAS  PubMed  Google Scholar 

  • Memtsoudis SG, Swamidoss C, Psoma M (2005) Anesthesia for adrenal surgery. In: Linos D, van Heerden JA (eds) Adrenal glands: diagnostic aspects and surgical therapy. Springer, New York, pp 287–297

    Chapter  Google Scholar 

  • Mozley PD, Kim CK, Mohsin J et al (1994) The efficacy of iodine-123- MIBG as a screening test for pheochromocytoma. J Nucl Med 35:1138–1144

    CAS  PubMed  Google Scholar 

  • Mukherjee JJ, Peppercorn PD, Reznek RH et al (1997) Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels. Radiology 202:227–231

    Article  PubMed  Google Scholar 

  • Mulligan LM, Ponder BA (1995) Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 80:1989

    CAS  PubMed  Google Scholar 

  • Nakamura K, Ogata M, Ando T, Usa T, Kawakami A (2011) Paroxysmal thyroid swelling. A forgotten clinical finding of pheochromocytoma. J Clin Endocrinol Metab 96(12):3601–3602

    Article  CAS  PubMed  Google Scholar 

  • Naswa N, Sharma P, Nazar AH, Agarwal KK, Kumar R, Ammini AC, Malhotra A, Bal C (2012) Prospective evaluation of 68Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study. Eur Radiol 22(3):710–719

    Article  PubMed  Google Scholar 

  • Neary N, King KS, Pack K (2011) Drugs and pheochromocytoma—don’t be fooled by every elevated metanephrine. N Engl J Med 364:23

    Article  Google Scholar 

  • Neumann HP, Pawlu C, Peczkowska M et al (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943

    Article  CAS  PubMed  Google Scholar 

  • Nölting S, Garcia E, Alusi G, Giubellino A, Pacak K, Korbonits M, Grossman AB (2012) Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. J Mol Endocrinol 49(2):79–96. doi:10.1530/JME-12-0028

    Article  PubMed  PubMed Central  Google Scholar 

  • Nölting S, Maurer J, Spöttl G, Aristizabal Prada ET, Reuther C, Young K, Korbonits M, Göke B, Grossman A, Auernhammer CJ (2015) Additive anti-tumor effects of lovastatin and everolimus in vitro through simultaneous inhibition of signaling pathways. PLoS ONE 10(12):e0143830. doi:10.1371/journal.pone.0143830, eCollection 2015

    Article  PubMed  PubMed Central  Google Scholar 

  • Pacak K (2007) Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 92:4069–4079

    Article  CAS  PubMed  Google Scholar 

  • Pacak K, Eisenhofer G, Ahlman H et al (2007) Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab 3(2):92–102

    Article  PubMed  Google Scholar 

  • Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giachè V, Mannelli M (2012) Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol 2012:872713, 10 pages. doi:10.1155/2012/872713

    Article  PubMed  PubMed Central  Google Scholar 

  • Perry CG, Sawka AM, Singh R, Thabane L, Bajnarek J, Young WF Jr (2007) The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. Clin Endocrinol (Oxf) 66:703–708

    Article  CAS  Google Scholar 

  • Pomares FJ, Cañas R, Rodriguez JM et al (1998) Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clin Endocrinol (Oxf) 48:195

    Article  CAS  Google Scholar 

  • Prys-Roberts C, Farndon JR (2002) Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg 26:1037–1042

    Article  PubMed  Google Scholar 

  • Sane T, Schalin-Jäntti C, Raade M (2012) Is biochemical screening for pheochromocytoma in adrenal incidentalomas expressing low unenhanced attenuation on computed tomography necessary? J Clin Endocrinol Metab 97(6):2077–2083. doi:10.1210/jc.2012-1061, Epub 2012 Apr 6

    Article  CAS  PubMed  Google Scholar 

  • Sawka AM, Jaeschke R, Singh RJ et al (2003) A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88:553–558

    Article  CAS  PubMed  Google Scholar 

  • Steinsapir J, Carr AA, Prisant LM, Bransome ED Jr (1997) Metyrosine and pheochromocytoma. Arch Intern Med 157:901–906

    Article  CAS  PubMed  Google Scholar 

  • Stolk RF, Bakx C, Mulder J, Timmers HJ, Lenders JW (2013) Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines? J Clin Endocrinol Metab 98(3):1100–1106. doi:10.1210/jc.2012-3669, Epub 2013 Feb 13

    Article  CAS  PubMed  Google Scholar 

  • Streeten DH, Anderson GH Jr (1996) Mechanisms of orthostatic hypotension and tachycardia in patients with pheochromocytoma. Am J Hypertens 9(8):760–769

    Article  CAS  PubMed  Google Scholar 

  • Strong VE, Kennedy T, Al-Ahmadie H et al (2008) Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 143(6):759–768

    Article  PubMed  Google Scholar 

  • Sutton MG, Sheps SG, Lie JT (1981) Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc 56:354

    CAS  PubMed  Google Scholar 

  • Sze WC, Grossman AB, Goddard I, Amendra D, Shieh SC, Plowman PN, Drake WM, Akker SA, Druce MR (2013) Sequelae and survivorship in patients treated with (131)I-MIBG therapy. Br J Cancer 109(3):565–572. doi:10.1038/bjc.2013.365, Epub 2013 Jul 16

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Thompson LDR (2002) Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26(5):551–566

    Article  PubMed  Google Scholar 

  • Timmers HJLM, Kozupa A, Eisenhofer G, Raygada M, Adams KT, Solis D, Lenders JWM, Pacak K (2007) Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-Associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 92(3):779–786

    Article  CAS  PubMed  Google Scholar 

  • Timmers HJ, Chen CC, Carrasquillo JA et al (2009) Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 94:4757–4767

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Volkin D, Yerram N, Ahmed F et al (2012) Partial adrenalectomy minimizes the need for long-term hormone replacement in pediatric patients with pheochromocytoma and von Hippel-Lindau syndrome. J Pediatr Surg 47:2077–2082

    Article  PubMed  Google Scholar 

  • Walther MM, Herring J, Enquist E et al (1999) von Recklinghausen’s disease and pheochromocytomas. J Urol 162:1582

    Article  CAS  PubMed  Google Scholar 

  • Whalen RK, Althausen AF, Daniels GH (1992) Extra-adrenal pheochromocytoma. J Urol 147:1

    CAS  PubMed  Google Scholar 

  • Yip L, Lee JE, Shapiro SE et al (2004) Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198:525–534

    Article  PubMed  Google Scholar 

  • Young WF Jr (2011) Endocrine hypertension. In: Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM (eds) Williams textbook of endocrinology, 12th edn. Elsevier Saunders, Philadelphia

    Google Scholar 

  • Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T, Kebebew E, Popovic V, Stratakis CA, Prchal JT, Pacak K (2012) Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 367(10):922–930. doi:10.1056/NEJMoa1205119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK

    P.T. Kavinga Gunawardane & Ashley Grossman

  2. Ministry of Health, Colombo, Sri Lanka

    P.T. Kavinga Gunawardane

Authors
  1. P.T. Kavinga Gunawardane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashley Grossman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashley Grossman .

Editor information

Editors and Affiliations

  1. Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

    Md. Shahidul Islam

  2. Department of Internal Medicine and Emergency Medicine, Uppsala University Hospital, Uppsala, Sweden

    Md. Shahidul Islam

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing AG

About this chapter

Cite this chapter

Gunawardane, P.K., Grossman, A. (2016). Phaeochromocytoma and Paraganglioma. In: Islam, M.S. (eds) Hypertension: from basic research to clinical practice. Advances in Experimental Medicine and Biology(), vol 956. Springer, Cham. https://doi.org/10.1007/5584_2016_76

Download citation

  • DOI: https://doi.org/10.1007/5584_2016_76

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-44250-1

  • Online ISBN: 978-3-319-44251-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation